CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Semaglutide 3mg and 7mg [Rybelsus] +1 moredrug
Likely dose
Semaglutide 3mg and 7mg [Rybelsus]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03919929
NCT03919929Phase 3Completed
CompareCT.gov

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

University of Colorado, Denver·interventional·Posted Apr 18, 2019·Updated Nov 25, 2025

In Brief

A Phase 3 clinical trial evaluating Semaglutide 3mg and 7mg [Rybelsus] and Weight loss diet for PCOS and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPCOS, Adolescent Obesity, NAFLD
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 18, 2019
Enrollment StartMay 3, 2019
Primary CompletionOct 3, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.2 years ago

Interventions

Semaglutide 3mg and 7mg [Rybelsus]drug

Once daily oral tablet of semaglutide for 4 months

Weight loss dietother

Prescribed weight loss diet to match weight loss in Drug arm